Articles from AIVITA Biomedical, Inc.

AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced a new study published in Cell Stem Cell describing a universal, stem cell-derived dendritic cell platform that can be personalized to an individual patient’s tumor and used to train the immune system to attack cancer. The study, “Engineered Human iPSC-Derived Dendritic Cells Dressed with Tumor MHC Complexes as a Cancer Vaccine,” was led by senior author Robert Blelloch, M.D., Ph.D., of UC San Francisco (UCSF), and includes AIVITA’s Krystal Godding, Gabriel I. Nistor, M.D., and Hans S. Keirstead, Ph.D. among its authors (Cell Stem Cell).

AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced the appointment of renowned physician, epidemiologist, technologist, philanthropist, and author Larry Brilliant, M.D., M.P.H., to its board of directors. Dr. Brilliant brings globally recognized expertise in epidemiology, pandemic preparedness, and vaccine readiness that is especially relevant to AIVITA’s multi-pathogen vaccine platform.

AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced that it has been named a 2026 Prix Galien USA nominee in the “Best Startup” category.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, is pleased to announce the execution of a licensing agreement with LevEllis, a global skincare retailer, for the worldwide exclusive marketing and distribution rights to AIVITA’s proprietary skincare formulations. Formerly sold as Root of Skin™, AIVITA’s skincare products generated strong market testing metrics amongst licensed clinical dermatologists and set records for consecutive sell-outs on QVC Japan.